Nine Diagnostics was selected to present at the Foundation for the NIH (FNIH) Biomarkers Consortium 20th Anniversary Symposium in Rockville, Maryland — a leading forum convening senior leaders across academia, industry, and government to advance biomarker science.
This selection reflects growing recognition of our platform within the broader biomarker ecosystem and our alignment with consortium-driven efforts to accelerate clinical validation and adoption.
The symposium emphasized the importance of moving beyond traditional single biomarkers toward integrated, data-driven approaches. As highlighted by keynote speaker Dr. Eliav Barr (Chief Medical Officer, Merck), the field is increasingly focused on scalable, clinically actionable biomarker strategies that can improve decision-making across drug development and patient care.
Nine Diagnostics’ nanosensor-driven, machine learning-enabled platform directly aligns with this shift — enabling the detection of complex molecular signatures that can support patient stratification, treatment selection, and response monitoring in oncology.
Link: [FNIH Symposium]
Link: YouTubeBiomarkers Consortium Symposium – Day 1: Keynote Address – Dr. Eliav Barr